Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
Trial ID or NCT#
This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine
Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer
- - Pancreatic tumors not to exceed 10 cm in greatest axial dimension - Histologically confirmed malignancies of the pancreas - Unresectable by CT criteria or exploratory laparotomy or laparoscopy - Patients with metastatic disease may be treated if they are symptomatic from the primary tumor - Performance status of 0, 1, or 2 - No chemotherapy two weeks prior or two weeks following radiosurgery
- - patients who have had prior radiotherapy to upper abdomen - patients receiving any prior pancreatic cancer therapy - children, pregnant, and breastfeeding women, and lab personnel are excluded - uncontrolled intercurrent illnesses - any concurrent malignancy
Contact us to find out if this trial is right for you.
View on ClinicalTrials.gov